Supporting an Early Diagnosis: Biomarkers in the Evaluation of the Early Alzheimer’s Disease
José Luis Molinuevo discuss the biomarker results from the patient case stufy. Jonathan Schott, MD, then introduces imaging and fluid biomarkers that can inform the diagnosis of Alzheimer’s disease. He evaluates the advantages and limitations of structural imaging in the context of Alzheimer’s disease and discusses the use of MRI and PET scans in the early diagnosis of Alzheimer’s disease. The biomarker results from the patient case study are then discussed. Lucilla Parnetti, MD, PhD, describes CSF biomarkers used to detect Alzheimer’s disease in the early stages and discusses the practical considerations relating to CSF biomarkers analysis. Jonathan Schott concludes by comparing CSF and amyloid PET imaging for the assessment of Alzheimer’s disease in the early stages.
Key Learning Objectives for Biogen’s AAT-AD/PD 2018 Symposium:
- Understand the importance of an early diagnosis of Alzheimer’s disease
- Gain insights on the use of cognitive assessment tools to achieve an early diagnosis of Alzheimer’s disease
- Understand how fluid and imaging biomarkers can be used to achieve an accurate and timely diagnosis of Alzheimer’s disease in the early stages
- Increase understanding of management options for patients diagnosed with Alzheimer’s disease in the early stages
Disclosure: All panelists received honoraria from Biogen for participation in this symposium.
Disclaimer: All of the information discussed today is for informational purposes only; does not constitute medical advice; and is not intended to be a substitute for independent professional medical judgment, advice, diagnosis, or treatment.
